Summary It is now recognised that epithelial-stromal interactions are important in a wide range of disease processes including neoplasia and inflammation. Metalloproteinases are central to matrix degradation and remodelling, which are key events in tumour invasion and metastasis and may also be involved in tissue changes occurring in chronic inflammation. Immunohistochemistry was performed on sections from 50 patients with pancreatic cancer (n = 27), ampullary cancer (n = 12), low bile duct cancer (n = 3), neuroendocrine tumours (n= 3) and chronic pancreatitis (n = 5), using antibodies raised against collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of metalloproteinase (TIMPI) and developed using the avidin-biotin complex method.Abundance of MMP2, MMP3 and TIMPI was greater in pancreatic and ampullary cancer than any other pathology and immunoreactivity in the malignant epithelial cells in pancreatic and ampullary cancer was greater than in the stromal tissues (in pancreatic cancer: MMP2 100% vs 37%, MMP3 93% vs 15%, TIMPI 93% vs 4%, P<0.0001). There were strong correlations between the immunoreactivity of the two antibodies for MMP2 (P<0.0001), between MMP2 and TIMPI (P<0.0001) and between MMP3 and TIMPI (P< 0.0001). The immunoreactivity for TIMPI in pancreatic and ampullary cancers with lymph node metastases was significantly less compared with those cases without lymph node metastases (P< 0.02) and there was an association between increased immunoreactivity for MMP2 and the degree of tumour differentiation (P<0.01). The results implicate MMP2, MMP3 and TIMPI in the invasive phenotype of pancreatic and ampullary cancer.
Ductal adenocarcinoma of the pancreas is the fifth most common cause of cancer death in the western world (Haddock and Carter, 1990) . Fewer than 10% of pancreatic cancers are resectable at the time of presentation, and even after resection the 5 year survival rate is only 10-15%. Periampullary cancers (arising from the ampulla of Vater or lower bile duct) are much less common than pancreatic cancer; they are often resectable and are associated with 5 year survival rates of 30% or more (Russell, 1990) . The better outcome from ampullary cancer may be related to earlier presentation as survival for both types of cancer is strongly correlated with tumour grade, local invasion and lymph node metastasis (Neoptolemos et al., 1988; Yamaguchi and Enjoji, 1989) .
The ability of malignant epithelial cells to break down adjacent extracellular matrix (ECM) (Hart et al., 1989 ) is an essential step in the processes of invasion and metastasis (Liotta et al., 1980; Liotta and Stetler-Stevenson, 1991) . Loss of basement membrane integrity in breast and colorectal cancers have been shown to be associated with an increased risk of metastasis and poor prognosis (Charpin et al., 1986; Forster et al., 1986) . In pancreatic cancers discontinuous or absent basement membrane type IV collagen is seen more frequently than in benign disease (Lee et al., 1994) , and pancreatic cancer is characterised by aggressive local behaviour, early metastasis and an intense desmoplastic stromal reaction (Mollenhauer et al., 1987; Nagakawa et al., 1989 Nagakawa et al., , 1992 .
The matrix metalloproteinases (MMP) are a family of proteolytic enzymes that are capable of degrading different substrates within the ECM (Cottam and Rees, 1993) and play a major role in the process of invasion and metastasis (Liotta et al., 1991) . The functional activity of the activated forms of these enzymes appear to be controlled by three specific tissue inhibitors of metalloproteinases (TIMPI, 2, 3) (Cottam and Rees, 1993; Uria et al., 1994) . The cellular source of MMPs is often difficult to identify in complex tissues. MMP1 (type I collagenase) appears to be a product of fibroblasts (Biswas, 1982) , some tumour cell lines, including the pancreatic cancer cell line SUIT2 (Taniguchi et al., 1992) and colonic tumours (Gray et al., 1993) . MMP9 (92 kDa type IV collagenase) is also a product of some cancer cell lines (Okada et al., 1990 (Okada et al., , 1992 Shima et al., 1993) , squamous cell carcinoma of the skin (Pyke et al., 1992) and prostate adenocarcinoma (Hamdy et al., 1994) but also localises to tumour-infiltrating mononuclear cells, especially macrophages (Naylor et al., 1994) . MMP3 (stromelysin) cleaves collagen types III, IV, V and IX and degrades gelatin, fibronectin, laminin, elastin and proteoglycan link protein (Chin et al., 1985) . MMP3 has been shown to be produced by squamous cell carcinomas (Ostrowski et al., 1988; Matrisian et al., 1991) . MMP1O (stromelysin 2) may be expressed in tumours with an epidermoid component (Muller et al., 1988) , whereas MMP1 1 (stromelysin 3) is expressed in the stromal cells of breast cancer (Basset et al., 1990) and in colorectal malignancy (Urbanski et al., 1993) . MMP7 (Pump-1) is a smaller enzyme involved in uterine involution but also has a putative role in colonic cancer development (Yoshimoto et al., 1993) and is expressed by some colorectal line cells (Miyazaki et al., 1990) .
MMP2 (72 kDa type IV collagenase) activity is highly correlated with the invasive/metastatic phenotype. It is known to cleave basement membrane type IV collagen as well as V, VII, X and degrades gelatin, fibronectin, elastin and laminin (Murphy et al., 1991a,b) . MMP2 has been shown to be produced by fibroblasts (Overall et al., 1991) , endothelial cells (DeClerck et al., 1989; Unemori et al., 1992) and human cancer cell lines Zucker et al., 1990; Agarwal et al., 1994) but in human colorectal, breast and skin carcinomas most of the mRNA is found to localise to stromal fibroblasts (Poulsom et al., 1992 (Poulsom et al., , 1993 . This may be explained by cell-surface uptake by a putative receptor and membrane activation by a novel membraneassociated metalloproteinase (Sato et al., 1994) .
Since TIMPI and TIMP2 bind stoichiometrically with the activated form of the MMPs in a 1:1 ratio, small changes in the level of these enzymes may lead to biologically significant changes in proteolytic activity. TIMPI binds to the activated forms of MMP1, MMP3 and MMP9 (Welgus and Stricklin, 1983; Welgus et al., 1985; Wilhelm et al., 1989) , whereas TIMP2 inhibits both pro-MMP2 and activated MMP2 . Both TIMP1 and TIMP2 have been shown to be produced in cancer cell lines in vitro Ponton et al., 1991) and the epithelial component of human adenocarcinomas in vivo (Hewitt et al., 1991; Poulsom et al., 1992 Poulsom et al., , 1993 Zucker et al., 1992) . The intense stromal reaction associated with pancreatic cancer (Mollenhauer et al., 1987) and its aggressive local invasive characteristics (Nagakawa et al., 1992) , suggest that MMPs may play a role in the invasive phenotype of pancreatic cancer. This study reports the localisation of the protein products for MMP2, MMP3 and TIMPI in these different types of cancer using immunohistochemistry.
Materials and methods Antibodies Four monoclonal murine antibodies were used that are specific to the 72 kDa type IV collagenase (MMP2, antibodies GL22 and GL8), stromelysin 1 (MMP3, antibody Mac78) and the tissue inhibitor of the metalloproteinases (TIMPI, antibody Macl5). These antibodies were raised against recombinant enzymes and subsequently characterised by Western blotting. They were compared with all members of the MMP/TIMP family to confirm specificity and absorption controls with recombinant enzymes performed The murine avidin-biotin complex method was used for antigen detection with antibody dilutions of 1:100 for GL8 (stock solution 1.57 mg ml-' IgG), 1:40 for GL22 (stock solution 2.77 mg ml-' IgG), 1: 40 for Mac78 (stock solution 2.88 mg ml-' IgG) and 1:25 for MaciS (stock solution 1.75 mg ml-' IgG). Sections were dewaxed and rehydrated through ethanol, endogenous peroxidase was blocked with hydrogen peroxide and non-specific protein binding was reduced using goat serum. The primary antibody was applied at the correct dilution in a volume of 50-100 Ml and left overnight at 4°C. The primary antibody was removed and the sections washed in phosphate-buffered saline (PBS), biotinylated anti-murine goat antibody at a dilution of 1: 500 was applied to each section and left for 1 h (Dako, High Wycombe, UK). The sections were washed in PBS and streptavidin-labelled peroxidase at a dilution of 1: 500 was applied to the sections and left for 1 h (Dako). The sections were then washed for a third time in PBS and developed in 500 ml of 0.01% PBS, 0.025%, 3.3'-diaminobenzidine tetrahydrochloride (Sigma, Poole, UK) and 500 jl of 30% hydrogen peroxide. The sections were washed again in PBS, counterstained using haematoxylin, dehydrated through alcohol and mounted in Pertex (Cellpath, UK).
Specificity of immunostaining was established using a negative control for each section, missing out the primary antibody and using 100 Ml of the diluent alone. Also included in each batch of sections was a known positive control previously validated within the laboratory by parallel in situ hybridisation and/or enzymology.
Sections were taken from 50 individual patients: 27 with ductal adenocarcinoma of the pancreas, 12 with ampullary cancer, three with lower bile duct cancer, three with neuroendocrine pancreatic tumours and five with chronic pancreatitis (Table I ). All sections were stained with each antibody and scored independently by two individuals (GWHS, SRB) for intensity of staining of epithelial, stromal and normal tissue. Data were collected using the following scoring system: negative, 0; weak, 1/2; moderate, 3/4; strong, 5/6. The results were compared with TNM staging, tumour grade and tumour size.
Statistical analysis
Statistical analysis was performed using the Pearson chisquared test, the chi-squared test for trend and for other data using the Fisher's exact test where applicable (BMDP Statistical Software package and InStat by Graphpad).
Results
The tumour and lymph node stage and tumour differentiation and size are shown in Table I . The intensity of staining in each tissue type with each antibody for epithelial, stromal and adjacent normal cells are shown in Tables II and III. Immunoreactivities for MMP2, MMP3 and TIMPI were greatest in adenocarcinomas of pancreas and ampulla compared with those in the other pathologies. None of the neuroendocrine tumours stained more than weakly with any of the antibodies, except MMP3, for which one tumour stained moderately. The pattern of staining in low bile duct tumours was similar to that in adenocarcinomas of the pancreas and ampulla.
All of the chronic pancreatitis sections showed immuno reactivity in acinar and ductal epithelial components with each antibody, which for MMP2 and MMP3 was at least moderately strong in three out of five, whereas for TIMPI the epithelial staining was significant in only one out of five.
The immunoreactivity in the malignant epithelium was high with all of the antibodies in both adenocarcinomas of pancreas and ampulla (GL22 100% of pancreatic cases vs 100% of ampullary cases, GL8 100% vs 100%, Mac78 93% vs 92% and Maci5 93% vs 100%). In the malignant stromal tissue the immunoreactivity was much less (GL22 37% of pancreatic cases vs 17% of ampullary cases, GL8 40% vs 100%, Mac78 15% vs 34%, MaciS 4% vs 17%) and in normal tissue away from the malignant areas the immuno reactivity was even lower (GL22 15% of pancreatic cases vs 0% of ampullary cases, GL8 0% vs 0%, Mac78 4% vs 16%, MaciS 4% vs 33%) (Tables II and III) .
With each antibody the epithelial cell staining was significantly stronger than either stromal or normal cell staining in both adenocarcinomas of the pancreas (P<0.0001) and ampulla (P<0.003) and with each antibody there was a significant trend for epithelial cells to have moderate to strong staining, stromal cells to have moderate to weak staining and normal tissue to be negative (P<0.0001).
There was strong correlation between the immunoreactivity of the two MMP2 antibodies (P<0.0001) and between MMP2 (GL22 or GL8) and MMP3 (P<0.0001). There was also correlation of expression between MMP2 (GL22 or GL8) and TIMPI (P<0.0001) and between MMP3 and TIMPI (P<0.0001), but this was only significant when the data were considered as two groups, negative compared with any level of immunoreactivity. The generally low levels of immunoreactivity of TIMPI in the cancers and the small proportion of cases showing significant immunoreactivity justify this consideration.
Immunoreactivity for TIMP1 was absent or weak in 15 out of 16 cases of pancreatic cancer and four out of eight cases of ampullary cancer with lymph node metastases compared with eight out of 11 and one out of four cases respectively without lymph node metastases (P<0.02) (Table  IV) . There was increased immunoreactivity for MMP2 (GL8) with increasing tumour grade (P<0.01) ( Table V) .
There was no correlation or trend between lymph node stage or tumour differentiation and any of the other antibodies, nor between tumour stage and tumour size and any of the antibodies. 
Discussion
This study has shown the reactivity of the two antibodies recognising MMP2 significantly correlated, reflecting their specificity. The immunoreactivity of MMP2 and MMP3 also correlated and this was perhaps surprising, as these two enzymes have different substrate specificities (Cottam and Rees, 1993) and appear to be important in different diseases. MMP3 plays a role in the activation of other members of the MMP family (Murphy et al., 1987; Ito and Nagase, 1988) although not in the case of MMP2 where MT-MMP is a likely candidate (Sato et al., 1994) .
The antibodies to MMP2 (GL8 and GL22) both recognise pro-MMP2 and active MMP2 in solution phase, but in fixed tissues show a different reactivity pattern. GL22 demonstrates membrane and/or cytoplasmic staining which is polarised to the apex in differentiated cells, and rarely staining stromal cells while GL8 shows a cytoplasmic reactivity pattern in epithelial and stromal cells similar to other MMP2 antibodies that we have previously described (Poulsom et al., 1992) .
MMP2 has been shown to be produced by the RWP-1 human pancreatic cancer cell line . Plasma membrane fractions of the cell line were prepared by differential centrifugation and the membrane fraction extracted with N-butanol. Gelatin zymography showed proteinase bands of 92, 70 and 62 kDa and immunoblotting resulted in recognition of the 70 kDa protein but not the 92 kDa . It has been suggested that it is the membrane localisation of the MMP2 in the pancreatic cancer cells that is critical rather than the species of type IV collagenase (Zucker et al., 1992) . Certain human cancers have been shown to express MMP2, including adenocarcinoma of the colon, in which 10 out of 12 expressed the transcript for MMP2 but in desmoplastic fibroblasts rather than neoplastic cells. The same phenomenon was found in breast, skin and ovarian carcinomas (Poulsom et al., 1992 (Poulsom et al., , 1993 Naylor et al., 1994) . The role of MMP3 in human adenocarcinoma is not well documented, although it appears to be important in the progression of squamous cell carcinomas (Ostrowski et al., 1988) .
While immunoreactivities of both MMP2 and MMP3 (Figures 3 and 4) . The immunoreactivity of MMP3 and TIMPI also correlated, in keeping with previous studies (Wilhelm et al., 1989) . It has been shown previously in human pancreatic cancer cells that expression of MMP1 correlated with spontaneous metastatic ability (Taniguchi et al., 1992 ). An increase in type I collagenolytic activity was noted in a subclone of the human pancreatic cancer cell line SUIT2 that demonstrated an increased metastasising ability in nude mice (Taniguchi et al., 1992) . Reduced expression of TIMP is known to be associated with tumour cell line progression (Khokka et al., 1991) but evidence for this in human tumours has been lacking. A putative reduction in TIMPl expression in patients with lymph node metastasis from other cancer types has not been previously described. During the progression of tumours the check on proteolytic activity afforded by the specific enzyme inhibitors may be reduced, which allows a relatively greater proteolytic activity of MMP2 or other metalloproteinases (Liotta and StetlerStevenson, 1991) . The inverse relationship between tumour differentiation and expression of MMP2 provides further evidence of a central role for this enzyme in pancreatic and ampullary tumour progression.
These data strongly implicate MMP2, MMP3 and TIMPI in pancreatic and ampullary carcinoma progression. MMP2 immunoreactivity was directly related to tumour dedifferentiation (Figures 5 and 6 ) and invasive potential and reduced expression of its specific inhibitor (TIMPI) may be involved with increased metastatic ability. Although adenocarcinomas of the pancreas and ampulla of Vater show distinct differences in clinical outcome the present study supports the notion that these differences may be related to the stage of clinical presentation or biological characteristics other than the expression of MMP2, MMP3 and TIMPl.
